Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries

British Journal of Clinical Pharmacology

Volumn 41, Issue 2, 1996, Pages 101-107

  He, Guo Wei ^a   Yang, Cheng Qin ^b   Gately, Hugh ^b   Furnary, Anthony ^b   Swanson, Jeffery ^b   Ahmad, Aftab ^b   Floten, Storm ^b   Wood, James ^b   Starr, Albert ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

Mammary artery; Milrinone; Nitroglycerin; Phosphodiesterase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; GLYCERYL TRINITRATE; MILRINONE; PHOSPHODIESTERASE INHIBITOR;

ARTICLE; HUMAN; HUMAN TISSUE; MAMMARY ARTERY; MUSCLE CONTRACTION; MUSCLE RELAXATION; PRIORITY JOURNAL; SMOOTH MUSCLE; VASODILATATION;

EID: 0030042258     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00166.x     Document Type: Article

References (42)

1. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Ann Rev Pharmacol Toxicol 1985; 25: 171-191.
2. Hardman JG. Cyclic nucleotides and regulation of vascular smooth muscle. J Cardiovasc Pharmacol 1984; 6: S639.
3. Maurice DH, Crankshaw D, Haslam RJ. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur J Pharmacol 1991; 192: 235-242.
4. Maurice DH, Haslam RJ. Molecular basis of the greater than additive inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671.
5. Beavo JA, Reifsnyder DH. Primary sequences of cyclic nucleotide phosphodiesterases isozymes and the design of selective inhibitors. Trends Pharmacol Sci 1990; 11: 150-5.
6. Beavo JA. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Second Messenger Phosphoprot Res 1988; 22: 1-38.
7. Dundore RL, Pagani ED, Bode DC, et al. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005. J Cardiovasc Pharmacol 1995; 25: 14-21.
8. Edelson J, Stroshane R, Benziger DP, et al. Pharmacokinetics of the bipyridines amrinone and milrinone. Circulation 1986; 73: (suppl III), III-145-52.
9. Silver PJ, Lepore RE, O'Connor B, et al. Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone. J Pharmacol Exp Ther 1988; 247: 34-42.
10. Silver PJ. Biochemical aspects of inhibition of cardiovascular low km cyclic adenosine monophosphate phosphodiesterase. Am J Cardiol 1989; 63: 2A-8A.
11. Pagani ED, Dundore RL, Bode DC, et al. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582. J Cardiovasc Pharmacol 1994; 24: 403-410.
12. Loop FD, Thomas JD. Hypoperfusion after arterial bypass grafting. Ann Thorac Surg 1993; 56: 812-813.
13. Sarabu MR, McClung JA, Fass A, Reed GR. Early postoperative spasm in left internal mammary artery bypass grafts. Ann Thorac Surg 1987; 44: 199-200.
14. He G-W, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein, and coronary artery to constrictor and dilator substances: Relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol 1988; 12: 12-22.
15. 1-adrenoceptor mediated contraction in the human internal mammary artery. J Cardiovasc Pharmacol 1993; 21: 256-263.
16. He G-W, Acuff TE, Ryan WH, et al. Inhibitory effects of calcium antagonists on α-adrenoceptor mediated contraction in the internal mammary artery. Br J Clin Pharmacol 1994; 37: 173-179.
17. a-adrenoceptor mediated contraction in the internal mammary artery. Br J Clin Pharmacol 1992; 34: 236-243.
18. He G-W, Yang C-Q, Mack MJ, Acuff TE, Ryan WH, Starr A. Interaction between endothelin and vasodilators in the human internal mammary artery. Br J Clin Pharmacol 1994; 38: 505-512.
19. 2 antagonist GR32191B on prostanoid and nonprostanoid receptors in the human internal mammary artery. J Cardiovasc Pharmacol 1995; 26: 13-19.
20. 2-Adrenoceptors and endothelium-dependent relaxation in canine large arteries. Br J Pharmacol 1986; 88: 767-77.
21. Likoff MJ, Weber KT, Andrews V, Janicki JS, Wilson H, Rocci ML. Milrinone in the treatment of chronic cardiac failure: A controlled trial. Am Heart J 1985; 110: 1035-1042.
22. 1ycerin in human plasma. Circulation 1979; 59: 588-592.
23. He G-W, Buxton B, Rosenfeldt F, Angus JA. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. Circulation 1989; 80(Suppl): I-141-I-150.
24. Ariëns EJ, van Rossum JM, Simonis AM: A theoretical basis of molecular pharmacology. Part II: interaction of one or two compounds with two independent receptor system. Arzneim-Forsch 19??: 6: 737-746.
25. Pöch G, Holzmann S. Quantitative estimation of overadditive and underadditive drug effects by means of theoretical, additive dose-response curves. J Pharmacol Methods 1980; 4: 179-188.
26. ACC/AHA. Guidelines for the early management of patients with acute myocardial infarction. Circulation 1990; 82: 667.
27. Alousi A, Canter J, Montenaro M, Fort D, Ferrari R. Cardiotonic activity of milrinone, a new potent cardiac bipyridine, on normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983; 5: 791-803.
28. Baim D, McDowell A, Cherline J, et al. Evaluation of a new bipyridineinotropic agent - milrinone - in patients with severe heart failure. N Engl J Med 1983; 309: 748.
29. Cody RJ, Muller FB, Kubo SH, Rutman H, Leonard D. Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. Circulation 1986; 73: 124-129.
30. Harris AL, Grant AM, Silver PJ, Evans, DB, Alousi A. Defferential vasorelaxant effects of milrinone and amrinone on contractile responses of canine coronary, cerebral, and renal arteries. J Cardiovasc Pharmacol 1989; 13: 238-244.
31. Komas N, Lugnier C, Stoclet J-C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nusleotide phosphodiesterase inhibitors. Br J Pharmacol 1991; 104: 495-503.
32. Fleming JS, Buyniski JP, Anagrelide. In: New drugs annual: cardiovascular drugs, ed Scirabine A, 277-294, Raven Press, New York, 1983.
33. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 1987; 61: 539-47.
34. Davies GC, Sobel M, Salzman EW. Elevated plasma fibrinopeptide a and thromboxane B2 levels during cardiopulmonary bypass. Circulation 1980; 61: 803-13.
35. Kamm KE, Stull JT. The function of myosin and myosin light chain kinase phosphorylation in smooth muscle. Ann Rev Pharmacol Toxicol 1985; 25: 593.
36. Murphy RA. Contraction in smooth muscle cells. Ann Rev Physiol 1989; 51: 275.
37. Dillon PF, Aksoy MO, Driska SP, Murphy RA. Myosin phosphorylation and the cross-bridge cycle in arterial smooth muscle. Science 1981; 211: 495.
38. Hai CM, Murphy RA. Cross-bridge phosphorylation and regulation of latch state in smooth muscle. Am J Physiol 1988; 254: C99.
39. Kawasuji M, Tedoriya T, Takemura H, Sakakibara N, Taki J, Watanabe Y. Flow capacities of arterial grafts for coronary artery bypass grafting. Ann Thorac Surg 1993; 56: 957-962.
40. He G-W, Yang C-Q, Starr A. Overview of the nature of vasoconstriction in arterial grafts for coronary surgery. Ann Thorac Surg 1995; 59: 676-683.
41. He G-W. Contractility of the human internal mammary artery at the distal section increases toward the end. Emphasis on not using the end of the IMA for grafting. J Thorac Cardiovasc Surg 1993; 106: 406-411.
42. He G-W, Yang C-Q. Comparison among arterial grafts and coronary artery. An attempt at functional classification. J Thorac Cardiovasc Surg 1995; 109: 707-715.